STANDARD BIOTOOLS INC. — Director's Dealing 2024

Jan 10, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: STANDARD BIOTOOLS INC. (LAB)
CIK: 0001162194
Period of Report: 2024-01-05

Reporting Person: Casdin Partners Master Fund, L.P. (Director, 10% Owner)
Reporting Person: Casdin Capital, LLC (Director, 10% Owner)
Reporting Person: Casdin Partners GP, LLC (Director, 10% Owner)
Reporting Person: Casdin Private Growth Equity Fund II, L.P. (Director)
Reporting Person: Casdin Private Growth Equity Fund II GP, LLC (Director)
Reporting Person: Casdin Private Growth Equity Fund, L.P. (Director)
Reporting Person: CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC (Director)
Reporting Person: Casdin Partners FO1-MSV, LP (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-05	Common Stock	A	11246525	—	Acquired	11246525	Direct
2024-01-05	Common Stock	A	2744219	—	Acquired	2744219	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1200000	Indirect

Footnotes

F1: Received in exchange for 10,132,005 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time"). The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.

F2: Received in exchange for 2,472,270 shares of common stock of SomaLogic pursuant to the Merger. Per the terms of the Merger, each share of SomaLogic common stock was converted pursuant to the Exchange Ratio at the Effective Time. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.

F3: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.